DUBAI & WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences Inc. announced today they have signed an exclusive strategic distribution agreement with the Alliance Global Group (AGBL) to help clinicians in emerging markets diagnose and manage a number of genetically based disorders. Courtagen’s test menu currently offers clinical tests for mitochondrial disorders (mtSEEK™ and nucSEEK™) and a newly released panel for epilepsy and seizure (epiSEEK™). Courtagen plans to add a number of key tests for other important neurological disorders.
“Building this relationship with AGBL is a critical component of Courtagen’s international business expansion,” said Brian McKernan, CEO, Courtagen Life Sciences, Inc.
Courtagen’s CLIA Laboratory genetic tests use next generation sequencing (NGS) technology, propriety bioinformatics platform, ZiPhyr™ and state of the art analytic capabilities to accurately sequence patient’s DNA and translate the sequence data into highly useful, clinically relevant information for physicians. Additionally, Courtagen’s protein diagnostics division offers decentralized testing of protein biomarker to simplify pre-clinical and clinical trial protocols.
“We are pleased to enter into this agreement with Courtagen,” said Dr. Tamer Degheidy, CEO of Alliance Global. “Courtagen’s portfolio of genetic tests will certainly have a positive impact on patients’ diagnosis and management in markets covered by our group.”
About Courtagen Life Sciences Inc.
Based in Woburn,
Massachusetts (USA), Courtagen Life Sciences is a privately held life
sciences company that provides innovative proteomic and genomic products
and services to the life sciences industry. Founded by innovators in
next-generation sequencing, genetics, molecular biology, and information
science, the company delivers tools to enable researchers and clinicians
to make better decisions regarding drug development and patient care.
For more information, please visit: www.courtagen.com
About Alliance Global Group (AGBL)
The AGBL Group of
companies is the largest biomedical gateway to the emerging markets of
Middle East, Africa and Asia. The group is dedicated to bringing the
latest technologies and products to researchers, clinicians, diagnostic
users and healthcare providers in the markets it covers. The group
employs more than 80 specialists and has six regional offices offering
distribution, consultation and product development services. The company
helps biomedical technology manufacturers and suppliers introduce their
products and services to emerging markets, reflecting on the healthcare
standards within those markets. For more information, please visit: www.agbl.net